Minghui Pharmaceutical (hangzhou) Ltd

This study tests a new drug called MHB009C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and how the body ha…

This study tests a new drug called MHB048C in 200 adults with advanced solid tumors (like prostate cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug by IV, and researchers m…

This study tests a new drug called MHB042C in 200 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug alone, and doctors monitor side effects and tum…

This Phase 3 trial tests MHB018A, an antibody injection, against placebo in 108 people with active moderate-to-severe thyroid eye disease. Participants receive six injections over 24 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 mm without worsening…

This study tests a drug called MHB018A for people with moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and discomfort. About 258 adults who completed earlier studies will receive injections every 4 weeks. The main goal is to see if the drug reduces…

This Phase 3 trial tests an injection called MHB018A for people with chronic moderate-to-severe thyroid eye disease. The drug targets a protein linked to inflammation and eye bulging. About 150 adults will receive either the drug or a placebo every 4 weeks for 6 months. The main …

This early-phase trial tests two experimental drugs, MHB088C and MHB039A, given together by IV to people with advanced solid tumors that no longer respond to standard treatments. The study has two stages: first, finding the safest dose, then checking if the combination can shrink…

This study tests two experimental drugs, MHB036C and MHB039A, given together to people with advanced breast cancer or other advanced solid tumors that have spread. The goal is to see if the combination is safe and can shrink tumors. About 210 adults aged 18 to 75 with measurable …

This study tests an experimental drug called MHB036C combined with other anti-cancer medicines in 300 people with advanced lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have tried standard treatments without success.

This study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.